

Special Issue

Bioactive Molecules for Targeted Cancer Therapy

Message from the Guest Editors

This Special Issue of *Molecules* is titled “Bioactive Molecules for Targeted Cancer Therapy”. The boom in nitrogen mustards at the start of the 20th century for cancer treatment was followed by the development of other chemotherapeutic agents. These drugs have limited ability to distinguish between cancer cells and normal cells, which results in systemic toxicity and off-target effects. With the advent of molecular and genomic sequencing, cancer treatment has shifted to molecularly targeted drugs. Bioactive molecules for targeted therapy range from small molecules as selective inhibitors of kinases, epigenetic regulatory proteins, DNA damage repair enzymes, and the proteasome to peptides, proteins, and other macromolecules. Computational chemistry and chemical biology have been important tools for the identification and validation of such small molecules as targeted drugs. In this Special Issue, we are seeking papers on recent developments in the synthesis, computational study, and evaluation of small molecules and macromolecules as targeted anti-cancer drugs. Communications, full-length research articles, and reviews are welcome.

Guest Editors

Dr. Goreti Ribeiro Morais

Institute of Cancer Therapeutics, Faculty of Life Sciences, University of Bradford, Bradford BD7 1DP, UK

Prof. Dr. Robert A. Falconer

Institute of Cancer Therapeutics, Faculty of Life Sciences, University of Bradford, Bradford BD7 1DP, UK

Deadline for manuscript submissions

31 July 2026



Molecules

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed



mdpi.com/si/249172

Molecules
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
molecules@mdpi.com

[mdpi.com/journal/
molecules](https://mdpi.com/journal/molecules)





Molecules

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed



[mdpi.com/journal/
molecules](https://mdpi.com/journal/molecules)



About the Journal

Message from the Editor-in-Chief

As the premier open access journal dedicated to molecular chemistry, now in its 30th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts, and novel materials. Pushing the boundaries of the discipline, we invite papers on all major fields of molecular chemistry and multidisciplinary topics bridging chemistry with biology, physics, and materials science, as well as timely reviews and topical issues on cutting-edge fields in all of these areas.

Editor-in-Chief

Prof. Dr. Thomas J. Schmidt

Institute of Pharmaceutical Biology and Phytochemistry, University of Münster, Corrensstrasse 48, D-48149 Münster, Germany

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Reaxys, CaPlus / SciFinder, MarinLit, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the second half of 2025).